Recombinant Cynomolgus/Rhesus Macaque B7-2/CD86 Protein, CF

When Recombinant Cynomolgus Monkey CTLA-4 Fc Chimera (Catalog # 9336-CT) is immobilized at 0.5 µg/mL, Recombinant CynomolgusMonkey/Rhesus Macaque B7‑2/CD86 Fc Chimera (Catalog # 9798-B2) bindswith an ED50 of 0.2-1 μg/mL.

• Reactivity: Pm-Cm, RM
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus/Rhesus Macaque B7-2/CD86 Protein, CF Summary

• Additional Information: Fc Chimera
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Cynomolgus Monkey CTLA-4 Fc Chimera (Catalog # 9336-CT) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Cynomolgus Monkey/Rhesus Macaque B7‑2/CD86 Fc Chimera (Catalog# 9798-B2) binds with an ED₅₀ of 0.2-1 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived B7-2/CD86 protein
  

  Cynomolgus Monkey/Rhesus Macque B7-2 (Leu20-His239) Accession # XP_005548057	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: XP_005548057
• N-terminal Sequence: Leu20
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 52 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 73-100 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in MOPS and NaCl with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus/Rhesus Macaque B7-2/CD86 Protein, CF

• Activation B7-2 antigen
• B70
• B7-2 antigen
• B72
• B7-2
• B-lymphocyte activation antigen B7-2
• BU63
• CD28 antigen ligand 2
• CD28LG2B7-2 antigen)
• CD86 antigen
• CD86 molecule
• CD86
• CTLA-4 counter-receptor B7.2
• FUN-1
• LAB72
• MGC34413
• T-lymphocyte activation antigen CD86

Background

B7-2, also known as CD86, B70, and ETC-1, is a 60-100 kDa variably glycosylated protein in the B7 family. B7 family members are transmembrane cell surface molecules that play important roles in immune activation and the maintenance of immune tolerance (1, 2). Within the ECD, cynomolgus B7-2 shares 96%, 57%, and 56% amino acid sequence identity with human, mouse and rat B7-2, respectively. B7-2 is highly expressed on activated antigen presenting cells (APC), e.g. B cells, dendritic cells, and monocytes (2-5), as well as on vascular endothelial cells (6). B7-2 and the closely related B7-1/CD80 exhibit overlapping but distinct functional properties. Their binding to CD28, which is constitutively expressed on T cells, enhances T cell receptor signaling and also provides TCR-independent co-stimulation (3, 5, 7-9). B7-1 and B7-2 additionally bind the CD28-related protein, CTLA-4, which is up‑regulated and recruited to the immunological synapse (IS) at the onset of T cell activation (3, 5, 7, 8). CTLA-4 ligation inhibits the T cell response and supports regulatory T cell function (10). B7-2 is expressed earlier than B7-1 following APC activation (4), and both proteins bind with higher affinity to CTLA-4 than to CD28 (8). B7-2 promotes the stabilization of CD28 in the IS, while B7-1 is primarily responsible for promoting CTLA-4 recruitment and accumulation in the IS (11). The relative participation of B7-1 and B7-2 in T cell co-stimulation can also alter the Th1/Th2 bias of the immune response (12). Both B7-1 and B7-2 serve as cellular receptors for B species adenoviruses (13).

1. Greenwald, R.J. et al. (2005) Annu. Rev. Immunol. 23:515.
2. Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
3. Freeman, G.J. et al. (1993) J. Exp. Med. 178:2185.
4. Lenschow, D.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90:11054.
5. Hathcock, K.S. et al. (1993) Science 262:905.
6. Seino, K. et al. (1995) Int. Immunol.7:1331.
7. Chen, C. et al. (1994) J. Immunol. 152:4929.
8. Lanier, L.L. et al. (1995) J. Immunol. 154:97.
9. Rudd, C.E. et al. (2009) Immunol. Rev. 229:12.
10. Wing, K. et al. (2011) Trends Immunol. 32:428.
11. Pentcheva-Hoang, T. et al. (2004) Immunity 21:401.
12. Kuchroo, V.K. et al. (1995) Cell 80:707.
13. Short, J.J. et al. (2006) Virus Res. 122:144.

Bioinformatics

• Uniprot:
  • XP_005548057()